These results established that GLP1R agonism could be used to improve metabolism and modestly lower body weight in patients with obesity while reducing cardiovascular risk, building upon the previously demonstrated success in improving cardiovascular outcomes in chronic treatment of T2D (refs76,177). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.